MedPath

BOOSTRIX-POLIO

BOOSTRIX-POLIO

Approved
DIN Number

02312557

Drug Class

Human

Market Date

Oct 22, 2010

Company
HC

GlaxoSmithKline Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02312557
AIG Number0852468001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D
A
ATC Code
J07CA02 DIPHTHERIA-PERTUSSIS-POLIOMYELITIS-TETANUS
Product Specifications
Dosage FormSuspension
Route of AdministrationIntramuscular
AHFS Classification80:12.00
Health Canada Classification

ACTIVE INGREDIENTS (8)

DIPHTHERIA TOXOID ADSORBEDActive
Strength: 2.5 LF / 0.5 ML
Monograph: DIPHTHERIA TOXOID ADSORBED
FILAMENTOUS HAEMAGGLUTININ ADSORBEDActive
Strength: 8 MCG / 0.5 ML
Monograph: FILAMENTOUS HAEMAGGLUTININ ADSORBED
INACTIVATED POLIOVIRUS TYPE IActive
Strength: 40 D / 0.5 ML
Monograph: INACTIVATED POLIOVIRUS TYPE I
INACTIVATED POLIOVIRUS TYPE IIActive
Strength: 8 D / 0.5 ML
Monograph: INACTIVATED POLIOVIRUS TYPE II
INACTIVATED POLIOVIRUS TYPE IIIActive
Strength: 32 D / 0.5 ML
Monograph: INACTIVATED POLIOVIRUS TYPE III
PERTACTIN ADSORBEDActive
Strength: 2.5 MCG / 0.5 ML
Monograph: PERTACTIN ADSORBED
PERTUSSIS TOXOID ADSORBEDActive
Strength: 8 MCG / 0.5 ML
Monograph: PERTUSSIS TOXOID ADSORBED
TETANUS TOXOID ADSORBEDActive
Strength: 5.0 LF / 0.5 ML
Monograph: TETANUS TOXOID ADSORBED

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.